Arcus Biosciences Inc (RCUS) Stock Price, Quote & News

Company Profile

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; and Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 694 6200

Website: www.arcusbio.com

Address:

3928 Point Eden Way, Hayward, United States

TheGunnerAB Aug. 22 at 8:07 PM

$RCUS Anything but?

1 · Reply

ChuckBarrisJr Aug. 21 at 12:41 PM

$RCUS they skip doing a CC, but now announce they’re participating in 3 investor conferences all within a span of 1 week (9/3-9/10)?

1 · Reply

MRTunity Aug. 21 at 2:10 AM

$RCUS hit $11 in AH?! I don’t see such shares filled on Webull?! Idk 🤷‍♂️

0 · Reply

pchr Aug. 20 at 9:41 PM

$RCUS we hold the break out line surprisingly well, I did not expect that. For anyone interested in bars and lines, I recommend checking the chart from 19’, very interesting similarities.

0 · Reply

forprofit12 Aug. 19 at 5:00 PM

$RCUS can’t make heads or tails on the price action.

1 · Reply

ChuckBarrisJr Aug. 19 at 3:38 PM

$RCUS Mizuho raised their target to $45 yesterday - and it drops 5%?? I love extremely underpriced names, like this one, where retail hasn’t caught on to the true value yet. -all it takes is patience.

1 · Reply

MRTunity Aug. 19 at 2:00 AM

$RCUS are we going to finally snap out of this $9-$10 stranglehold and back up towards $14/$16 before Bo at $25-$30?!

1 · Reply

bryantboy99 Aug. 16 at 12:09 AM

$AUPH $CTMX $ETON $RCUS great day headed into the weekend

3 · Reply

pchr Aug. 15 at 8:02 PM

$RCUS no we talking! break out in progress?

2 · Reply

keepindadreamalive Aug. 15 at 4:51 PM

$RCUS new three month high yeah baby, let’s go

0 · Reply

Arcus Biosciences to Participate in Three Upcoming Investor Conferences

Aug 14, 2025, 8:07 AM EDT - 10 days ago

Jim Cramer Recommends This Energy Stock, But Don't 'Bank It All' On Arcus

UEC

Aug 10, 2025, 9:34 AM EDT - 14 days ago

Arcus Biosciences: A Risky Buy Ahead Of Pivotal, Catalyst-Rich 12 Months

Aug 6, 2025, 4:05 PM EDT - 18 days ago

Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update

Jul 24, 2025, 4:35 PM EDT - 4 weeks ago

Arcus Biosciences Announces New Employment Inducement Grants

Jul 10, 2025, 8:30 AM EDT - 6 weeks ago

Arcus Biosciences' Quemliclustat Receives Orphan Drug Designation for Pancreatic Cancer

Jun 1, 2025, 10:45 AM EDT - 3 months ago

Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response

May 6, 2025, 8:17 PM EDT - 3 months ago

Arcus Biosciences, Inc. (RCUS) Q1 2025 Earnings Call Transcript

May 6, 2025, 4:05 PM EDT - 3 months ago

Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update

Apr 23, 2025, 4:05 PM EDT - 4 months ago

Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting

Apr 22, 2025, 4:05 PM EDT - 4 months ago

Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update

Apr 2, 2025, 3:48 PM EDT - 5 months ago

Arcus Biosciences: A High-Risk Speculation With Multiple Large, Near-Term Catalysts

Feb 26, 2025, 4:35 PM EST - 6 months ago

Arcus Biosciences to Participate in Two Upcoming Investor Conferences

Feb 25, 2025, 4:05 PM EST - 6 months ago

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update

Feb 18, 2025, 6:57 AM EST - 6 months ago

Arcus Biosciences Retains Rights to Casdatifan, a Potential Best-in-Class HIF-2a Inhibitor, and Announces Pricing of $150 Million Common Stock Offering

Feb 18, 2025, 6:52 AM EST - 6 months ago

Arcus Biosciences, Inc. Announces Underwritten Offering of Common Stock

Feb 15, 2025, 3:45 PM EST - 6 months ago

New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer

Feb 10, 2025, 5:00 PM EST - 6 months ago

Arcus Biosciences to Present New Data from Casdatifan, a HIF-2a Inhibitor, in an Oral Presentation at the 2025 ASCO GU Symposium

Jan 21, 2025, 4:05 PM EST - 7 months ago

Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical Officer

Jan 14, 2025, 10:51 PM EST - 7 months ago

Arcus Biosciences: Many Important Oncology Catalysts Coming Up In 2025

Jan 13, 2025, 8:00 AM EST - 7 months ago

Arcus: Excellent Pipeline And Collaborations, Cash Runway

Dec 19, 2024, 4:05 PM EST - 8 months ago

Arcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Nov 6, 2024, 11:39 PM EST - 10 months ago

Arcus Biosciences, Inc. (RCUS) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:22 PM EST - 10 months ago

Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update

Nov 5, 2024, 9:00 AM EST - 10 months ago

Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer

Oct 30, 2024, 9:00 AM EDT - 10 months ago

Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting

Oct 24, 2024, 7:30 AM EDT - 10 months ago

First Clinical Data for Arcus Biosciences' HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer

Oct 22, 2024, 4:05 PM EDT - 10 months ago

Arcus Biosciences to Host Conference Call to Discuss Third-Quarter 2024 Financial Results and Pipeline Update

Oct 9, 2024, 8:00 AM EDT - 11 months ago

Arcus Biosciences to Present First Clinical Data from ARC-20 Study at the 2024 EORTC-NCI-AACR Symposium

Oct 2, 2024, 4:05 PM EDT - 11 months ago

Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma

AZN

Sep 23, 2024, 1:53 AM EDT - 1 year ago

Arcus Biosciences Looks Compelling Ahead Of Key Clinical Oncology Milestones

Aug 27, 2024, 4:05 PM EDT - 1 year ago

Arcus Biosciences Secures Up to $250 Million Term Loan Facility from Hercules Capital

HTGC

Aug 9, 2024, 5:31 PM EDT - 1 year ago

Arcus Biosciences: Getting Too Cheap To Ignore (Reiterate Buy)

Aug 9, 2024, 5:21 PM EDT - 1 year ago

Arcus Biosciences, Inc. (RCUS) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:05 PM EDT - 1 year ago

Arcus Biosciences Reports Second-Quarter 2024 Financial Results and Provides a Pipeline Update

Jul 25, 2024, 4:05 PM EDT - 1 year ago

Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2024 Financial Results and Pipeline Update

Jul 8, 2024, 6:00 PM EDT - 1 year ago

Taiho Pharmaceutical Exercises Option for an Exclusive License to Quemliclustat in Japan and Certain Territories in Asia

Jun 10, 2024, 8:30 AM EDT - 1 year ago

Arcus Biosciences Completes Patient Enrollment in Phase 3 Trial Evaluating a Domvanalimab-Containing Regimen in First-Line Metastatic Upper GI Cancers

Jun 6, 2024, 4:05 PM EDT - 1 year ago

Arcus Biosciences to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Jun 2, 2024, 8:00 AM EDT - 1 year ago

Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer

GILD

Jun 1, 2024, 8:00 AM EDT - 1 year ago

Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers

GILD

May 8, 2024, 9:55 PM EDT - 1 year ago

Arcus Biosciences, Inc. (RCUS) Q1 2024 Earnings Call Transcript

May 8, 2024, 4:02 PM EDT - 1 year ago

Arcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update

May 2, 2024, 4:05 PM EDT - 1 year ago

Arcus Biosciences to Participate in the Bank of America Healthcare Conference 2024

Apr 24, 2024, 4:00 PM EDT - 1 year ago

Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting

Apr 23, 2024, 4:05 PM EDT - 1 year ago

Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline Update

Feb 22, 2024, 2:08 AM EST - 1 year ago

Arcus Biosciences, Inc. (RCUS) Q4 2023 Earnings Call Transcript

Feb 21, 2024, 4:05 PM EST - 1 year ago

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline Update

Feb 7, 2024, 5:00 PM EST - 1 year ago

Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2023 Financial Results and Pipeline Updates

Jan 29, 2024, 6:20 PM EST - 1 year ago

Gilead Sciences raises stake in cancer-centric Arcus Biosciences to 33%

GILD

TheGunnerAB Aug. 22 at 8:07 PM

$RCUS Anything but?

1 · Reply

ChuckBarrisJr Aug. 21 at 12:41 PM

$RCUS they skip doing a CC, but now announce they’re participating in 3 investor conferences all within a span of 1 week (9/3-9/10)?

1 · Reply

MRTunity Aug. 21 at 2:10 AM

$RCUS hit $11 in AH?! I don’t see such shares filled on Webull?! Idk 🤷‍♂️

0 · Reply

pchr Aug. 20 at 9:41 PM

$RCUS we hold the break out line surprisingly well, I did not expect that. For anyone interested in bars and lines, I recommend checking the chart from 19’, very interesting similarities.

0 · Reply

forprofit12 Aug. 19 at 5:00 PM

$RCUS can’t make heads or tails on the price action.

1 · Reply

ChuckBarrisJr Aug. 19 at 3:38 PM

1 · Reply

MRTunity Aug. 19 at 2:00 AM

$RCUS are we going to finally snap out of this $9-$10 stranglehold and back up towards $14/$16 before Bo at $25-$30?!

1 · Reply

bryantboy99 Aug. 16 at 12:09 AM

$AUPH $CTMX $ETON $RCUS great day headed into the weekend

3 · Reply

pchr Aug. 15 at 8:02 PM

$RCUS no we talking! break out in progress?

2 · Reply

keepindadreamalive Aug. 15 at 4:51 PM

$RCUS new three month high yeah baby, let’s go

0 · Reply

Kanguru Aug. 15 at 3:13 PM

$RCUS refreshing week

0 · Reply

TheGunnerAB Aug. 12 at 2:06 AM

$RCUS down from 10M

1 · Reply

TheGunnerAB Aug. 12 at 2:04 AM

$RCUS Short Interest 8.96M down from 19M two weeks prior.

1 · Reply

keepindadreamalive Aug. 8 at 10:22 PM

$RCUS check out the OI on $15 call Ex 4/17/26

1 · Reply

pchr Aug. 8 at 9:08 PM

$RCUS got excited and jumped in at 9.09. prolly will miss the nice entry at 8.70 but oh well, calculated risk

0 · Reply

MRTunity Aug. 8 at 7:53 PM

$VKTX 🙏 grateful I was buying back more at $26-$28 in mid June! Finally have a biotech NOT 💩 ing the bed like $SLS $RCUS

2 · Reply

ChuckBarrisJr Aug. 8 at 4:17 PM

$RCUS Cas alone puts this at $20+. TIGIT puts it at $250. Yep, I’m buying more shortly. I’m more patient than the coked up retards of WS and gladly use that patience to steal their funds.

1 · Reply

ChuckBarrisJr Aug. 7 at 7:30 PM

$RCUS I’ll keep adding - I thank the WS bastards who are providing such a rare opportunity to get in cheaply!

0 · Reply

rabbitsoup Aug. 7 at 5:11 PM

$RCUS Does anyone here know the short position at $RCUS?

2 · Reply

Mountaineer96 Aug. 7 at 3:52 PM

$RCUS I am just going to put my money in something stable like bitcoin or Tesla

1 · Reply

Diplo Aug. 7 at 3:01 PM

$RCUS what are the avg prices on the december and april huge OI calls?

1 · Reply

ChuckBarrisJr Aug. 7 at 2:42 PM

$RCUS ok, I’ll bite. I’ll add.

0 · Reply

Market Cap	1.12B
Revenue (ttm)	258.00M
Net Income (ttm)	-283.00M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-109.69%
Debt to Equity Ratio	0.18

Volume	726,900
Avg Vol	888,408
Day's Range	N/A - N/A
Shares Out	106.43M
Stochastic %K	74%
Beta	0.89
Analysts	Strong Sell
Price Target	$29.00